Tolerance of transcranial direct current stimulation in psychiatric disorders: An analysis of 2000+ sessions

•Transcranial direct current stimulation (tDCS) is a non-invasive, neuromodulatory technique.•tDCS is increasingly being applied in several psychiatric disorders.•Safety and tolerance profile of tDCS in 2005 sessions in 171 patients (156-adult & 15 adolescents) is analyzed.•Psychiatric diagnoses...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Psychiatry research 2020-02, Vol.284, p.112744-112744, Article 112744
Hauptverfasser: Chhabra, Harleen, Bose, Anushree, Shivakumar, Venkataram, Agarwal, Sri Mahavir, Sreeraj, Vanteemar S., Shenoy, Sonia, Hazari, Nandita, Dinakaran, Damodharan, Parlikar, Rujuta, Koparde, Vinayak, Ramesh, Vinutha, Biswal, Jitendriya, Murugaraja, Venkatachalam, Gowda, Shayanth Manche, Chand, Prabhat K., Sivakumar, Palanimuthu T., Kalmady, Sunil V, Narayanaswamy, Janardhanan C., Murthy, Pratima, Girimaji, Satish C., Venkatasubramanian, Ganesan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Transcranial direct current stimulation (tDCS) is a non-invasive, neuromodulatory technique.•tDCS is increasingly being applied in several psychiatric disorders.•Safety and tolerance profile of tDCS in 2005 sessions in 171 patients (156-adult & 15 adolescents) is analyzed.•Psychiatric diagnoses included schizophrenia, obsessive-compulsive disorder, mild cognitive impairment, depression and dementia.•tDCS related adverse effects are mild, transient and well-tolerated. Transcranial direct current stimulation (tDCS), a non-invasive, neuromodulatory technique, is being increasingly applied to several psychiatric disorders. In this study, we describe the side-effect profile of repeated tDCS sessions (N = 2005) that were administered to 171 patients (156 adults and 15 adolescents) with different psychiatric disorders [schizophrenia [N = 109], obsessive-compulsive disorder [N = 28], alcohol dependence syndrome [N = 13], mild cognitive impairment [N = 10], depression [N = 6], dementia [N = 2] and other disorders [N = 3]]. tDCS was administered at a constant current strength of 2 mA with additional ramp-up and ramp-down phase of 20 s each at the beginning and end of the session, respectively. Other tDCS protocol parameters were: schizophrenia and obsessive-compulsive disorder: 5-days of twice-daily 20-min sessions with an inter-session interval of 3-h; Mild cognitive impairment/dementia and alcohol dependence syndrome: at least 5-days of once-daily 20-min session; Depression: 10-days of once-daily 30 min session. At the end of each tDCS session, any adverse event observed by the administrator and/or reported by the patient was systematically assessed using a comprehensive questionnaire. The commonly reported adverse events during tDCS included burning sensations (16.2%), skin redness (12.3%), scalp pain (10.1%), itching (6.7%), and tingling (6.3%). Most of the adverse events were noted to be mild, transient and well-tolerated. In summary, our observations suggest that tDCS is a safe mode for therapeutic non-invasive neuromodulation in psychiatric disorders in adults as well as the adolescent population.
ISSN:0165-1781
1872-7123
DOI:10.1016/j.psychres.2020.112744